Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma

Exclusion Criteria

• •Previously treated with chemotherapy containing anthracycline, with or without rituximab
• •ECOG performance status 0 to 2
• •With a minimum life expectancy of 3 months
• •Having signed informed consent form prior to enrollment
• •Burkitt's, mantle cell, T-cell lymphomas
• •CD 20-negative lymphoma
• •HIV or HBV related disease
• •Central nervous system or meningeal involvement by the lymphoma
• •Not previously treated with anthracycline-containing regimens
• •Contraindication to any drug contained in the R-GEMOX chemotherapy regimen
• •Any serious active disease or co-morbid medical condition (according to the investigator's decision),
• •Poor renal function (creatinine level \> 150micromol/l), poor hepatic function (total bilirubin level \> 30mmol/l, transaminases \> 2.5 maximum normal level) unless these abnormalities are related to the lymphoma
• •Poor bone marrow reserve as defined by neutrophils \< 1.5 G/l or platelets \< 100 G/l, unless related to bone marrow infiltration
• •Any history of cancer during the last 5 years, with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma
• •Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study
• •Any radiotherapy during the four weeks before inclusion
• •Pregnant or lactating woman
• •Adult patient unable to give informed consent because of intellectual impairment.